NCT02059265 2023-08-01Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal CancerNational Cancer Institute (NCI)Phase 2 Terminated35 enrolled 13 charts
NCT00671788 2016-04-15A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CarcinomaGOG FoundationPhase 2 Completed35 enrolled 8 charts